Title
|
|
|
|
**In vitro** antibacterial activity of the ceftazidime-avibactam (NXL104) combination against **Pseudomonas aeruginosa** clinical isolates
|
|
Author
|
|
|
|
|
|
Abstract
|
|
|
|
The beta-lactamase inhibitor avibactam (NXL104) displays potent inhibition of both class A and C enzymes. The in vitro antibacterial activity of the combination ceftazidime-avibactam was evaluated against a clinical panel of Pseudomonas aeruginosa isolates. Avibactam offered efficient protection from hydrolysis since 94% of isolates were susceptible to ceftazidime when combined with 4 mu g/ml avibactam, compared with 65% susceptible to ceftazidime alone. Ceftazidime-avibactam also demonstrated better antipseudomonal activity than imipenem (82% susceptibility), a common reference treatment. |
|
|
Language
|
|
|
|
English
|
|
Source (journal)
|
|
|
|
Antimicrobial agents and chemotherapy. - Washington, D.C., 1972, currens
|
|
Publication
|
|
|
|
Washington, D.C.
:
American Society for Microbiology
,
2012
|
|
ISSN
|
|
|
|
0066-4804
|
|
DOI
|
|
|
|
10.1128/AAC.06064-11
|
|
Volume/pages
|
|
|
|
56
:3
(2012)
, p. 1606-1608
|
|
ISI
|
|
|
|
000300623300063
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|